Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Lotus Purchases Ulcer Drug for $7.9 Million

publication date: Feb 19, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Lotus Pharmaceuticals (路坦制药有限公司) has bought the rights to Yipubishan, an octreotide acetate injection solution, that treats the symptoms of gastric ulcers and hemorrhages of the upper digestive tract. Lotus paid 54 million RMB ($7.9 million) for the drug.  That was less than its 2008 revenues, which were 67 million RMB ($9.8 million) with a 75% gross profit margin. Lotus projects 75 million RMB of revenue from Yipubishan in 2009 and a 25% per year growth rate through 2011. More details...

Stock Symbol:  (OTCBB: LTUS)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at this event:
 
 
Hope to see you there!
 
ChinaBio® Events
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors